Jeenatara Begum. et.al, International Journal of Engineering Research and Applications*
www.ijera.com
ISSN: 2248-9622, Vol. 15, Issue 5, May 2025, pp 98-108

RESEARCH ARTICLE OPEN ACCESS

Impact of Gingipains in Alzheimer's Disease: A Comprehensive Review

SkMijanurRahaman, Jeenatara Begum*
Guru Nanak Institute of Pharmaceutical Science & Technology
157/F Nilgunj Road, Panihati, Kolkata – 700114

Abstract:
Alzheimer's disease (AD) is a progressive neurological illness that causes a substantial loss of independence in those who have it. It is characterized by behavioral abnormalities, memory impairment, and cognitive decline. Amyloid-beta (Aβ) plaque build-up and neurofibrillary tangles made of hyperphosphorylated tau have historically been used to explain the pathophysiology of AD. Recent studies, however, have expanded this perspective to include inflammatory and viral processes as possible causes. *Porphyromonasgingivalis*, a keystone pathogen in chronic periodontitis, is one of the most attractive microbiological possibilities. An growing number of studies have connected AD-related disease to gingipains, a class of cysteine proteases that are its main virulence factors. It has been shown that gingipains break neuronal proteins including tau and amyloid precursor protein (APP), disrupt the blood-brain barrier (BBB), and activate neuroinflammatory pathways, all of which increase the development of plaque and tau aggregation. Peripheral infection and central neurodegeneration are reflected in these processes. Using information from clinical research, animal models, and genetic studies, this review critically analyzes the mechanistic involvement of gingipains in the development of AD. It also highlights the significance of oral-systemic health integration in the prevention ofneurodegenerative diseases and examines contemporary treatmentapproaches that target gingipains.
Keywords: Alzheimer's disease, gingipains, *Porphyromonasgingivalis*, neuroinflammation, amyloid-beta, tau pathology, periodontitis, blood-brain barrier.

Date of Submission: 06-05-2025 Date of acceptance: 18-05-2025

I. Introduction:

The leading cause of dementia globally is Alzheimer's disease (AD), a chronic, degenerative brain disorder. Due to global aging trends, its prevalence is predicted to triple by 2050, impacting over 55 million people [1]. Clinical features of AD include executive dysfunction, memory loss, language issues, and a chronic cognitive decline that ultimately results in mortality and loss of independence. Amyloid-beta (Aβ) plaque formation and hyperphosphorylated tau protein have been the two main neuropathological features of AD for many years. Nevertheless, despite focusing on these proteins, disease-modifying treatments have only partially succeeded, leading scientists to reevaluate the fundamental processes underlying the pathophysiology of AD [2,3].

According to recent research, AD is a complicated illness with intricate relationships between immunological, environmental, genetic, and microbiological components [4].Microbial infections and chronic systemic inflammation are increasingly being identified as variables that accelerate the onset of illness, even if age and the apolipoprotein E (APOE) ε4 allele remain important risk factors [5].

Porphyromonasgingivalis (P. gingivalis), an anaerobic, Gram-negative bacteria recognized for its involvement in chronic periodontitis, is one of the most well-known microbiological suspects in this context.[6] A frequent dental condition called periodontitis is linked to a systemic inflammatory state and results in the breakdown of the tissues that support teeth. Interestingly, observational studies have connected tooth loss and poor oral health to a higher risk of AD [6,7]. Through its virulence factors, which include gingipains, a family of strong cysteine proteases, *P. gingivalis* has been linked to neuroinflammation, tau and amyloid pathology, and blood-brain barrier (BBB) crossing [8,9].

The "infectious hypothesis" of AD suggests that persistent infections, such as those brought on by *P. gingivalis*, may function as upstream initiators of the tau and amyloid cascades.[9] This microbial model of ADemphasizes how crucial peripheral infections are in starting or speeding up neurodegenerative processes in the brain, especially those that cause low-grade but chronic systemic inflammation. According to this theory, gingipains

are important molecular actors that may affect the immunological and structural makeup of the central nervous system (CNS), rather than only being accessory poisons.[10]

We want to shed insight on the function of gingipains in Alzheimer's disease by investigating the connections between these virulence factors and important pathogenic proteins, immunological responses, and brain structures. We also examine the clinical and epidemiological data that links *P. gingivalis* to AD and evaluate the efficacy of existing and prospective gingipain-targeting treatment approaches.

II. Gingipains: Key Virulence Factors of P. gingivalis:

Gingipains are a class of strong cysteine proteases that *Porphyromonasgingivalis*secretes in order to be virulent. Based on their substrate specificity, these enzymes are divided into two main classes: lysine-specific gingipain (Kgp) and arginine-specific gingipain (RgpA and RgpB). The bacterium's colonization, survival, nutritional absorption, and host defense-evasion depend on these enzymes, which together make up over 85% of *P. gingivalis's* total proteolytic activity[11,12].

Gingipains were first investigated in relation to the deterioration of periodontal tissue, but they are now known to have systemic effects, especially in relation to neurodegenerative illnesses like Alzheimer's disease (AD).[13] *P. gingivalis* may spread to distant locations, including the brain, if it enters the circulation, often via ulcerated periodontal pockets. Gingipains are more easily delivered to the central nervous system because they are either directly produced or encapsulated in outer membrane vesicles (OMVs)[14].

Numerous harmful mechanisms in AD have been connected to gingipains, including:

- Disruption of the Blood-Brain Barrier (BBB): Gingipains degrade key tight junction proteins, such as occludin, claudin[14], and ZO, which weakens the BBB and facilitates the entry of inflammatory mediators and microbiological agents into the brain parenchyma.
- Induction of Neuroinflammation: Gingipains are known to activate toll-like receptors (TLR2 and TLR4) on microglial cells and astrocytes, which initiates an inflammatory cascade marked by elevated expression of proinflammatory cytokines like interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α). This results in persistent microglial activation, synapse loss, and neuronal dysfunction[15].
- Tau Aggregation and Cleavage: Gingipains promote the development of neurofibrillary tangles by cleaving tau protein at certain sites. Another crucial step in the pathogenesis of AD[16] is the hyperphosphorylation of tau, which is known to be caused by the kinases GSK-3β and CDK5. These kinases may also be indirectly activated by gingipain activity.
- Amyloidogenesis: Prolonged use of gingipains increases the expression of β-secretase (BACE1), increasing the production and deposition of amyloid-beta (Aβ) peptides[17] and improving amyloidogenic processing of amyloid precursor protein (APP). These peptides may then trigger an inflammatory loop that reinforces itself in the brain.
- Collectively, these mechanisms provide a robust mechanistic link between chronic periodontal infection and Alzheimer's disease. Gingipains are involved in brain amyloidogenesis, tau pathology, and neuroinflammation in addition to triggering local tissue death in the mouth cavity. Their varied functions make them important therapeutic targets in the search for effective AD therapies.

III. Entry of *P. gingivalis* and Gingipains into the Brain:

One of the most significant issues in the infectious hypothesis of Alzheimer's disease (AD) is how an oral infection, such *Porphyromonasgingivalis*, accesses the central nervous system (CNS). There have been many proposed entry locations, all supported by experimental data and anatomical plausibility. These include hematogenous spread, cerebral pathways, and exploiting a compromised blood-brain barrier (BBB).

3.1 Hematogenous Spread

The most widely used and well studied technique is hematogenous dispersion. Routine oral hygiene procedures, such as brushing, flossing, biting, and especially dental procedures, may cause transient bacteremia, which are episodes in which *P. gingivalis* enters the circulation. In healthy individuals, these episodes are short-lived, and the immune system gets rid of the bacteria. However, individuals with systemic inflammation and periodontal disease may have bacteremia more often and for a longer duration, increasing the likelihood that microbial components may reach distant organs, including the brain[18].

P. gingivalis may interact with vascular endothelial cells, particularly those that comprise the blood-brain barrier, after it has entered the circulation. The barrier's permeability is increased by gingipains, LPS, and outer membrane vesicles (OMVs) by weakening tight junctions and dissolving structural proteins such as occludin and claudin[19]. This permeability may allow toxins, inflammatory mediators, and microbial antigens to enter the

central nervous system (CNS) and interact with neural cells.

3.2 Neuronal Transport

Another possibility is retrograde axonal transport via cranial nerves, namely the olfactory and trigeminal nerves. These neurons provide a close connection between the nose and oral canals and the brainstem and olfactory bulb. Many pathogens, including *P. gingivalis*, have used this mechanism. Experimental study has shown the presence of bacterial DNA and antigens in areas associated with these brain circuits[20].

Importantly, olfactory impairment is one of the first signs of AD, and it has been proposed that infections that enter via the olfactory nerve may result in early neurodegenerative changes. This channel is an efficient, although devious, way to get into the central nervous system since it totally circumvents the BBB.

3.3 Compromised Blood-Brain Barrier

The integrity of the BBB deteriorates with age, and neuroinflammatory and neurodegenerative disorders exacerbate its impairment. Cognitive decline is linked to early BBB breakdown in Alzheimer's disease, regardless of amyloid burden. *P. gingivalis* exploits this vulnerability by using its virulence factors, such as gingipains[21], to further erode the barrier and permit deeper CNS invasion.

Once within the brain, *P. gingivalis*or its components, especially OMVs, may be found in areas that are often affected by AD, such as the hippocampus and cerebral cortex. LPS, DNA, RNA, and gingipains are among these vesicles, and they are all connected to oxidative stress, tau hyperphosphorylation, amyloid-beta accumulation, and local inflammation[22].

These three pathwayshematogenous, neuronal, and via a weakened blood-brain barrierall highlight the manner in which a chronic oral infection may travel to the brain and perhaps contribute to the sequence of events that leads to Alzheimer's disease.

IV. Gingipains and Neuroinflammation

The role of neuroinflammation in the development and course of Alzheimer's disease (AD) is becoming more well acknowledged. It is now thought to be a primary cause of neuronal damage, synaptic dysfunction, and cognitive decline, having previously been thought to as a subsequent reaction to amyloid-beta (Aβ) buildup. Microbial triggers like gingipains, which are released by *Porphyromonasgingivalis*, have drawn special attention among the many factors that cause neuroinflammation because of their strong immunostimulatory qualities.

Both resident immune cells in the brain and biochemical pathways that support chronic inflammation may be activated by gingipains. Gingipains activate astrocytes and microglia upon entering the brain parenchyma, causing them to adopt a proinflammatory (M1-like) phenotype. Increased production of cytokines such tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) results from this phenotypic change, and these cytokines combined cause neuronal injury and impede synaptic plasticity[23,24].

The NLRP3 inflammasome is one important mechanism by which gingipains increase neuroinflammation. This intracellular sensor activates caspase-1 and causes IL-1β and IL-18 to mature when it recognizes microbial components and danger-associated molecular patterns (DAMPs). In vitro and in animal models, gingipains have been shown to persistently stimulate this pathway, causing tissue damage and chronic microgliosis[25,26].

Furthermore, persistent neuroinflammation hinders microglia's capacity to effectively remove extracellular Aβ. Microglia take involvement in the phagocytosis and breakdown of Aβ under normal circumstances. However, their phagocytic activity deteriorates when gingipains and other inflammatory stimuli continuously activate them, which exacerbates the neurodegenerative cascade and causes further Aβ accumulation[26,27].

Hippocampal microgliosis, dendritic spine loss, synaptic degeneration, and memory impairment are among the classic AD-like alterations that have been seen in experimental research conducted on mice exposed to gingipain-expressing *P. gingivali*.Importantly, these neuroinflammatory effects were decreased by pharmacological suppression of gingipains, confirming their causative involvement in beginning CNS inflammation[28].

Things considered, our results show that gingipains are active neuroimmune disruptors that may cause persistent brain inflammation, a hallmark of AD etiology, rather than only being byproducts of oral infections.

V. Gingipains and Tau Pathology:

One of the characteristics of Alzheimer's disease (AD) is the abnormal accumulation of hyperphosphorylated tau protein, which results in intracellular neurofibrillary tangles (NFTs). These tangles destabilize the cytoskeleton and interfere with axonal transport, which directly leads to

neuronal dysfunction and death. According to recent research, tau pathology may result from a number of factors, including microbial components such the gingipains that *Porphyromonasgingivalis*releases, as well as having a downstream effect of amyloid-beta (Aβ).

5.1 Direct Cleavage of Tau by Gingipains

Gingipains, due to their strong proteolytic activity, gingipains have the ability to directly cleave tau at certain hexapeptide patterns. These cleaved fragments often adopt misfolded, aggregation-prone conformations, which serve as nucleation sites for further tau fibril formation[29]. This direct enzymatic interaction changes tau's normal physiological function and facilitates the formation and dissemination of hazardous tau oligomers throughout neurons.

5.2 Promotion of Indirect Hyperphosphorylation

In addition to directly breaking tau, gingipains can indirectly contribute to tau disease by inducing intracellular kinases that lead to tau hyperphosphorylation. Notably, gingipain-induced neuroinflammation is associated with increased levels of kinases including glycogen synthase kinase-3 beta (GSK-3β) and cyclin-dependent kinase 5 (CDK5). Tau phosphorylation at AD-relevant locations has been strongly associated with these kinases[30]. The loss of hyperphosphorylated tau's ability to attach to microtubules causes axonal degeneration and microtubule instability.

5.3 Facilitation of Prion-like Tau Spread

According to recent studies, tau has prion-like properties; misfolded tau may spread from neuron to neuron, causing the native tau in recipient cells to misfold. The inflammatory environment that gingipain activity creates, particularly via NLRP[31] inflammasome activation and cytokine signaling, seems to facilitate its propagation. Inflammatory cytokines such as IL-1β may enhance tau production and cause pathological tau species to be released extracellularly.

Experimental evidence supports these mechanisms. Long-term oral contact with *P. gingivalis* raises tau phosphorylation and accumulation in brain regions that are often affected in AD, according to research on animals. Additionally, gingipain inhibition has been shown to decrease tau pathology, hence validating the enzyme's role in tau-related neurodegeneration[32].

Our findings together suggest that gingipains are not passive observers of tau dysregulation but rather actively participate in it. They do this by both directly and indirectly affecting the inflammatory environment that promotes tau disease by changing the structure of tau.

VI. Gingipains and Amyloid-Beta Accumulation:

Research on Alzheimer's disease (AD) has long focused on the amyloid-beta (Aβ) peptide, with the amyloid cascade hypothesis positing that the disease process begins with the buildup of this peptide. Although there have been new discussions over the importance of Aβ in AD, its role in the disease is still indisputable. New data suggests that microbial agents, namely *Porphyromonasgingivalis* and its gingipain proteases, may affect Aβ dynamics on many levels, expanding our knowledge of Aβ deposition and metabolism.

6.1 Amyloidogenic APP Processing Promotion

Gingipains upregulate beta-site APP cleaving enzyme 1 (BACE1), a crucial enzyme that produces Aβ peptides, hence indirectly promoting the amyloidogenic cleavage of amyloid precursor protein (APP). Gingipain-induced inflammatory cytokines, including TNF-α and IL-1β, may increase BACE1 expression via NF-κB-mediated pathways[33,34]. The hazardous Aβ42 isoform, which is prone to oligomerization and plaque formation in the brain, is produced in greater quantities as a result.

6.2 Aβ Clearance Impairment

In addition to boosting output, gingipains disrupt the natural processes that remove Aβ. Microglia's capacity to phagocytose and digest extracellular Aβ is compromised by chronic neuroinflammation. Furthermore, apolipoprotein E (ApoE) and other essential proteins involved in the transport and clearance of Aβ across the blood-brain barrier are broken down by gingipains[35]. Extracellular Aβ accumulation and persistence in susceptible brain areas such as the cortex and hippocampus are facilitated by this disturbance.

6.3 Pro-inflammatory Environment Favoring Plaque Formation

Aggregation and stability of Aβ fibrils are supported by the oxidative stress and cytokine-rich milieu that gingipain-induced neuroinflammation produces. Reactive oxygen species (ROS) are released by gingipain-activated microglia, altering Aβ and increasing its aggregation potential[36,37]. Neurodegeneration is accelerated by this positive feedback loop, which also perpetuates amyloid buildup and chronic inflammation.

6.4 Amyloid-Beta as an Antimicrobial Response

Remarkably, new research indicates that Aβ could have developed as a component of the innate immune system. Aβ has antibacterial qualities and may be generated in reaction to microbial invasion, such as that caused by *P. gingivalis.* In this context, Aβ functions similarly to other antimicrobial peptides, such as defensins[38], in that it traps and neutralizes invasive bacteria. However, Aβ turns from a protective to a pathogenic agent when it is overproduced as a result of inflammation or persistent infections, aggregating form insoluble plaques[39].

According to this antimicrobial theory, amyloid buildup is no longer a merely harmful result but rather an immune-mediated response. It supports the notion that long-term infections like periodontal disease might serve as upstream catalysts in the etiology of Alzheimer's disease.

VII. Clinical and Epidemiological Evidence:

Porphyromonasgingivalis and its gingipain proteases have been linked more and more in clinical and epidemiological research to the etiology of Alzheimer's disease (AD).[40,41] In postmortem brain tissues of AD patients, gingipain proteins and *P. gingivalis* DNA have been found by a number of independent studies. These findings show a significant concentration in areas that are important for cognition, including the hippocampus and temporal cortex.[42] These results strongly support the idea that AD disease has an infectious component by pointing to a direct microbial presence inside the central nervous system.

Additionally, serological investigations have shown that AD patients have much greater levels of antibodies against gingipains than cognitively healthy controls. Prolonged or recurring oral infections may be the cause of elevated antibody titers, which show systemic and perhaps chronic exposure to *P. gingivalis* antigens.[44,45] Crucially, these immune reactions are linked to more rapid cognitive loss and higher hippocampus shrinkage, indicating that gingipain exposure may not only be a biomarker but also a factor in the development of the illness.

The amount of tau pathology and the gingipain burden in the brain are positively correlated, according to quantitative research. The idea that these bacterial enzymes may worsen or perhaps cause tau-related neurodegenerative processes is supported by the finding that gingipain concentrations correlate with tau hyperphosphorylation levels and neurofibrillary tangle density.

In support of these conclusions, a large number of cross-sectional and longitudinal investigations have shown that people with chronic periodontitis have a much higher risk of dementia and cognitive impairment.[46] Reduced performance on memory and executive function tests has been linked to periodontal disease, which is characterized by ongoing local inflammation and higher systemic cytokine levels. Furthermore, tooth loss-particularly when caused by periodontitis-has become a valid indicator of cognitive deterioration in later life.[47,48] The independent significance of dental health in neurodegenerative disease risk is highlighted by these relationships, which hold true even after adjusting for important confounders including age, education, smoking status, and cardiovascular comorbidities.

Over a follow-up period of 10-20 years, those who have fewer than ten teeth left or who practice poor dental hygiene are almost twice as likely to acquire Alzheimer's disease, according to evidence from population-based research. Additionally, individuals with a history of severe periodontitis often have heightened levels of AD-typical cerebrospinal fluid (CSF) indicators,[49] such as decreased Aβ42 and increased total tau, which connect peripheral infection to central biomolecular alterations.

The idea that *P. gingivalis* and its gingipains are not only indicators of infection but also possible causes of AD pathology through processes including systemic inflammation, disruption of the blood-brain barrier, and direct neurotoxicity is strongly supported by these clinical and epidemiological data taken together.[50,51]

VIII. Therapeutic and Preventive Approaches:

Porphyromonasgingivalis and its gingipain proteases are increasingly implicated in the pathogenesis of Alzheimer's disease (AD),[52] leading to the development of novel preventive and therapeutic strategies that focus on the oral pathogen and its virulence mechanisms. The goal of these strategies is to stop the infectious-inflammatory cascade that is connected to neurodegeneration.[52,53] These strategies include immunization, pharmacological inhibition, antimicrobial therapies, and oral hygiene promotion.

8.1 Gingipain Inhibitors

The primary cause of *P. gingivalis* neurotoxicity is gingipains, namely the proteases Rgp and Kgp,[54] which are specific to arginine and lysine. Blocking these enzymes has been shown to have potential therapeutic advantages. One of the most advanced drugs in this family is COR388 (atuzaginstat), a small-molecule inhibitor that

selectively inhibits gingipain activity.[55] In preclinical AD animal models, COR388 treatment led to a significant improvement in cognitive performance, a decrease in neuroinflammation, a reduction in tau and amyloid-beta pathology, and a significant decrease in the bacterial load in the brain. These findings provide significant support for the idea that gingipains cause the neuropathological and behavioral signs of AD.[56]

Phase 1 and phase 2 clinical investigations in humans have shown that COR388 is generally well tolerated and may slow the rate of cognitive decline in individuals with early-stage AD who test positive for *P. gingivalis*.[57] Despite the conflicting results of later-phase studies, the therapeutic concept of gingipain inhibition is currently being researched for improvement and precise targeting[58].

8.2 Antimicrobial Strategies

Additionally, antimicrobial methods have been used to lessen the burden of *P. gingivalis* in the oral cavity. Systemic antibiotics, such doxycycline, a tetracycline derivative with anti-inflammatory properties, have shown benefits in reducing the levels of periodontal bacteria and the associated systemic inflammation.[59] However, their efficacy is limited by issues such as bacterial resistance, commensal microbiota modification, and insufficient blood-brain barrier penetration.[60,61]

Systems for delivering medications locally have gained interest as a remedy for these problems. Chlorhexidine gels, minocycline microspheres, and slow-release chips all provide a high local antibacterial concentration with little systemic exposure when applied directly into periodontal pockets.[62,63] These targeted medications have been shown to reduce gingival inflammation and *P. gingivalis* colonization, which may interfere with the pathway from oral infection to inflammation of the central nervous system.

8.3 Vaccination Techniques

Experimental vaccines that target gingipains or other virulence factors, including as outer membrane vesicles (OMVs) and fimbrial proteins, have shown immunogenicity in preclinical animals.[64] Mice immunized with recombinant gingipain proteins produced high titers of protective antibodies, which prevented systemic dissemination and associated neuroinflammatory responses in addition to reducing oral bacterial loads.[65] Due to their multivalent antigen presentation, OMV-based vaccines may have broader protective effects and enhance immune system recognition.[66,67]

Moreover, oral or intranasal mucosal vaccination may prevent germs from adhering to periodontal tissues by producing local secretory IgA responses. Although they are still in the early phases of study, gingipain-based vaccinations provide a novel preventive approach to lower the risk of AD at the microbial entry site.

8.4 Oral hygiene and preventive dentistry

Strict dental hygiene is one of the simplest and most affordable preventive measures. Brushing, flossing, and routine dental exams reduce gingival inflammation, break down microbial biofilms, and prevent the progression of periodontitis.[68] Population-based studies have shown that improved oral hygiene habits are linked to a lower incidence of AD and cognitive impairment. A healthy oral microbiota, a decreased risk of bacteremia,[69] and a decrease in systemic inflammatory markers are likely the causes of these benefits.

Furthermore, it has been shown that expert periodontal care, such as scaling and root planing, enhances systemic health indicators including C-reactive protein (CRP) and interleukin-6 (IL-6),[70] both of which are connected to neurodegenerative processes. Importantly, these therapies are broadly applicable and available, making them vital components of public health campaigns aimed at reducing the incidence of dementia.[71,72]

8.5 Expanded Implications for Neuroprotection

Together, these therapeutic and preventive strategies suggest that treating oral infections—particularly those caused by *P.gingivalis* and its gingipains-may change brain neurodegenerative pathways in addition to periodontal outcomes. Future research should focus on integrating these tactics into more all-encompassing frameworks for AD prevention,[73] especially for at-risk populations.

IX. Prospects for the Future:

A number of exciting new directions for future study, diagnosis, and treatment development are made possible by the mounting evidence that *Porphyromonasgingivalis*[75]and its gingipains are linked to Alzheimer's disease (AD). Both scientific research and healthcare systems need to move toward proactive, integrative, and individualized techniques in order to convert present results into clinically useful outcomes.

9.1 Early Detection via Microbiome Profiling

High-resolution analysis of the oral microbiome is now possible because to developments in metagenomic sequencing and bioinformatics. The development of microbial risk signatures, especially those involving *P. gingivalis* abundance,[76] diversity metrics, or virulence gene

expression patterns, should be the main focus of future study. Years before cognitive symptoms appear, at-risk groups may be identified early by identifying dysbiotic oral microbiomes that predispose them to systemic inflammation and neurodegeneration. In order to bridge the gap between oral and brain health, these microbial indicators might potentially be included in screening instruments used in general care or dentistry settings.

9.2 Genetic Risk Stratification and Precision Medicine

A well-known genetic risk factor for AD, the APOE ε4 allele may also affect a person's vulnerability to periodontal disease and reaction to microbiological stimuli. Future research should examine how microbial exposure and host genetics combine to influence AD risk and development.[76,77] Precision medicine techniques that focus early periodontal screening, preventive gingipain inhibitor medication, or tailored immunomodulatory therapies for persons with APOE ε4 may be made possible by this. Adapting therapy and preventative care to microbial and genetic profiles may greatly enhance results and postpone the start of illness.

9.3 Establishing Causality via Longitudinal Cohort Studies

Despite the strength of the present data, our capacity to infer causation is limited since a large portion of it is still observational or cross-sectional. It is crucial to do long-term prospective cohort studies that monitor systemic inflammation, dental health status, microbiome composition, and cognitive outcomes throughout time.[78] Confounders including socioeconomic position, nutrition, cardiovascular health, and education should also be controlled for in these investigations. Validating treatment targets and guiding public health policy will need establishing a distinct temporal link between *P. gingivalis* colonization and neurodegenerative alterations.[78,79]

9.4 Multifactorial Pathology Combination Therapies

Because AD is a complicated and multifaceted condition, gingipain-targeting monotherapies may not be enough. Future therapeutic paradigms need to investigate combination strategies that include gingipain inhibitors with other substances such blood-brain barrier protectors, tau aggregation inhibitors, or anti-inflammatory medications.[79] By treating host immune responses, downstream neuropathology, and microbial triggers all at once, these combination treatments may have synergistic benefits. Clinical trials in patient subgroups identified by biomarkers should be conducted after preclinical models have been utilized to evaluate such therapies methodically.

9.5 Translational And Multidisciplinary Cooperation

The need of multidisciplinary cooperation is shown by the connection between neurodegeneration and oral microbiology. To create integrated models of treatment, neurologists, microbiologists, immunologists, dentists, geriatricians, and public health specialists must collaborate.[80,81] Dental practitioners may be crucial in screening and early referral as they are often the first to identify persistent periodontitis. In the meanwhile, neurologists should include periodontalevaluations into cognitive risk profile and be aware of the possible oral-systemic links. In order to turn bench-side findings into bedside applications, collaborative networks and translational research activities will be essential.

X. Conclusion:

Our knowledge of neurodegeneration has undergone a dramatic change as a result of the correlation between gingipains and Alzheimer's disease (AD). Previously identified as a major contributor to periodontitis, *Porphyromonasgingivalis* has recently been shown to be a plausible pathogenic factor in AD and cognitive decline. Gingipains seem to affect many interrelated pathways that are essential to the pathophysiology of AD via mechanisms such disruption of the blood-brain barrier, microglial activation, cleavage of tau protein, and overproduction of amyloid-beta.

This changing viewpoint urges researchers and clinicians to take persistent oral infections into account as modifiable, upstream drivers of neurodegenerative processes, challenging the traditional emphasis on genetics and aging alone.There is an urgent need to incorporate microbial and immunological insights into Alzheimer's research, prevention, and treatment efforts as the body of data grows. Early identification, multidisciplinary teamwork, and innovative therapeutic approaches-such as gingipain-targeted treatments and strong public health campaigns encouraging dental hygiene-must be the top priorities of future research. By doing this, we may be able to improve the treatment of AD and open up new preventative options for one of the most difficult conditions of our day.

REFERENCES:

[1]. Jung S, Park H. Pathological implications of *Porphyromonasgingivalis* in Alzheimer's disease and therapeutic potential of gingipain inhibitors. Oral Biol Res. 2025

[2]. Shawkatova I, Durmanova V, Javor J. Alzheimer's Disease and *Porphyromonasgingivalis*: Exploring the Links. *Life*. 2025;15(1):96. doi:10.3390/life15010096.

[3]. Sarmiento-Ordóñez JM, [Additional Authors]. Association Between *Porphyromonasgingivalis* and Alzheimer's Disease: A Comprehensive Review. *Infect Drug Resist*. 2025

[4]. Zhang P, Liu Y, Jin X, Hu Z, Yang J. Alzheimer's disease-like pathology induced by *Porphyromonasgingivalis* in middle-aged mice is mediated by NLRP3 inflammasome via the microbiota-gut-brain axis. *J Alzheimers Dis*. 2025

[5]. Park J, Kim S, Lee SM, Baek H, Shin DS. Rapid detection of Lys-gingipain using fluorogenic peptide substrate for diagnosis of periodontitis. *J Dent Sci*. 2025

[6]. Melo A, Flores-Fraile J, Lo Giudice R, Marchetti E, Nart J, Greethurst AR, Real-Voltas F, Tarallo F, Galletti C. Association Between Alzheimer's Disease and Periodontal Inflammatory Parameters: A Systematic Review. J Clin Exp Dent. 2025 Mar 1;17(3):e310–e323.

[7]. Li F, Ma C, Lei S, Pan Y, Lin L, Pan C, Li Q, Geng F, Min D, Tang X. Gingipains may be one of the key virulence factors of *Porphyromonasgingivalis* to impair cognition and enhance blood–brain barrier permeability: An animal study. *J Clin Periodontol*. 2024 Jul;51(7):818–839.

[8]. Nonaka S, Okamoto R, Katsuta Y, Kanetsuki S, [Additional Authors]. Gingipain-carrying outer membrane vesicles from *Porphyromonasgingivalis* cause barrier dysfunction of Caco-2 cells by releasing gingipain into the cytosol. *BiochemBiophys Res Commun*. 2024;

[9]. Grobler C. The role of gingipains, a bacterial inflammagen, in clotting pathology noted in Alzheimer's disease [dissertation]. Stellenbosch (South Africa): Stellenbosch University; 2023.

[10]. Sabbagh MN, Decourt B. COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease. *Expert OpinInvestig Drugs*. 2022 Oct;31(10):987–993. doi:10.1080/13543784.2022.2117605.

[11]. Peng S. Gingipain of *Porphyromonasgingivalis* exacerbates features of Alzheimer's disease and affects the level of TREM2 via amyloid-β. *Int J Eng*. 2022;8(2):180–187.

[12]. Olsen I. Porphyromonasgingivalis-induced neuroinflammation in Alzheimer's disease. *Front Neurosci*. 2021;15:691016.

[13]. Kanagasingam S, Chukkapalli SS, Welbury RR, Singhrao SK. Porphyromonasgingivalis is a strong risk factor for Alzheimer's disease. *J Alzheimers Dis Rep*. 2020;4(1):501–511.

[14]. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ. Porphyromonasgingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. *Sci Adv*. 2019 Jan 4;5(1):160806.

[15]. Harding A, Robinson S, Crean S, et al. Can better management of periodontal disease delay the onset and progression of Alzheimer's disease? J Alzheimers Dis. 2017;58:337–348.

[16]. Harding A, Gonder U, Robinson SJ, et al. Exploring the association between Alzheimer's disease, oral health, microbial endocrinology and nutrition. Front Aging Neurosci. 2017;9:398.

[17]. Kitazawa M, Oddo S, Yamasaki TR, et al. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5 mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25:8843–8853.

[18]. Hanger DP, Byers HL, Wray S, et al. Novel phosphor ylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem. 2007;282(32):23645–23654.

[19]. Lee DC, Rizer J, Selenica ML, et al. LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflam. 2010;7:56.

[20]. Stein PS, Desrosiers M, Donegan SJ, et al. Tooth loss, dementia and neuropathology in the Nun study. J Am Dent Assoc. 2007;138:1314–1322.

[21]. Tzeng NS, Chung CH, Yeh CB, et al. Are chronic periodontitis and gingivitis associated with dementia? A nationwide, retrospective, matched-cohort study in Taiwan. Neuroepidemiology. 2016;47:82–93.

[22]. Blaizot A, Vergnes JN, Nuwwareh S, et al. Periodontal diseases and cardiovascular

events: meta-analysis of observational studies. Int Dent J. 2009;59(4):197–209.
[23]. Virtanen E, Nurmi T, Söder PÖ, et al. Apical period ontitis associates with cardiovascular diseases: a cross sectional study from Sweden. BMC Oral Health. 2017;17(1):107.
[24]. Macedo Paizan ML, Vilela-Martin JF. Is there an association between periodontitis and hypertension? CurrCardiol Rev. 2014;10(4):355–361.
[25]. Graziani F, Gennai S, Solini A, et al. Systematic review and meta-analysis of epidemiologic observational evidence on the effect of periodontitis on diabetes. An update of the EFP-AAP review. J Clin Periodontol. 2018;45(2):167–187.
[26]. Leira Y, Seoane J, Blanco M, et al. Association between periodontitis and ischemic stroke: a systematic review and meta analysis. Eur J Epidemiol. 2017;32(1):43–53.
[27]. de la MonteSM.Type3diabetes issporadic Alzheimer's disease: mini-review. EurNeuropsychopharmacol. 2014;24(12):1954–1960.
[28]. Gatz M, Mortimer JA, Fratiglioni L, et al. Potentially modifiable risk factors for dementia in identical twins. Alzheimers Dement. 2006;2:110–117.
[29]. Chen C-K, Wu Y-T, Chang Y-C. Association between chronic periodontitis and the risk of Alzheimer's dis ease: a retrospective, population-based, matched cohort study. Alzheimers Res Ther. 2017;9:56.
[30]. Sparks Stein P, Steffen MJ, Smith C, et al. Serum antibo dies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement.2012;8:196–203.
[31]. Dunn N, Mullee M, Perry H, et al. Association between dementia and infectious disease: evidence from a case control study. Alzheimer Dis Assoc Disord. 2005;19(2):91–94.
[32]. Noble JM, Borrell LN, Papapanou PN, et al. Periodontitis is associated with cognitive impairment among older adults: analysis of NHANES-III. J NeurolNeurosurg Psychiatry. 2009;80:1206–1211.
[33]. Watts A, Crimmins EM, Gatz M. Inflammation as a potential mediator for the association between period ontal disease and Alzheimer's disease. Neuropsychiatr Dis Treat. 2008;4:865–876.
[34]. Kamer AR, Craig RG, Pirraglia E, et al. TNFα and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal sub jects. J Neuroimmunol. 2009;216:92–97.
[35]. Ide M, Harris M, Stevens A, et al. Periodontitis and cognitive decline in Alzheimer's disease. PLoS One. 2016;11(3):e0151081.
[36]. Aas JA, Paster BJ, Stokes LN, et al. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol. 2005;43(11):5721–5732.
[37]. Rogers GB, Bruce KD. Exploring the parallel develop ment of microbial systems in neonates with cystic fibrosis. MBio. 2012;3(6):e00408–e00412.
[38]. Miklossy J. Chronic inflammation and amyloidogenesis in Alzheimer's disease– role of spirochetes. J Alzheimers Dis. 2008;13:381–391.
[39]. Miklossy J. Historic evidence to support a causal relationship between spirochetal infections and Alzheimer's disease. Front Aging Neurosci. 2015;7:46.
[40]. Poole S, Singhrao SK, Kesavalu L, et al. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tis sue. J Alzheimers Dis. 2013;36:665–677.
[41]. Murphy MP, LeVine H. Alzheimer's disease and the β amyloid peptide. J Alzheimers Dis. 2010;19:311–323.
[42]. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766.
[43]. Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer dis ease. J Clin Invest. 2002;110:1375–1381.
[44]. Rossor MN, Newman S, Frackowiak RS, et al. Alzheimer's disease families with amyloid precursor protein mutations. Ann NY Acad Sci. 1993;695:198 202.
[45]. Hook V, Kindy M, Reinheckel T, et al. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem 2009;386:284–288. Biophys Res Commun.
[46]. Mueller-Steiner S, Zhou Y, Arai H, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron. 2006;51:703–714.
[47]. Ishida N, Ishihara Y, Ishida K, et al. Periodontitis induced by bacterial infection exacerbates features of Alzheimer's disease in transgenic mice. NPJ Aging Mech Dis. 2017;3:15.

[48]. Hook V, Schechter I, Demuth HU, et al. Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol Chem. 2008;389:993–1006.
[49]. Hook V, Hook G, Kindy M. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's dis ease. Biol Chem. 2010;3391:861–872.
[50]. Hook G, Hook V, Kindy M. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. J Alzheimers Dis. 2011;26:387–408.
[51]. HookV,Funkelstein L, Wegrzyn J, et al. Cysteine cathepsins in the secretory vesicle produce active peptides: cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer'sdis ease. BiochimBiophys Acta. 2012;1824:89–104.
[52]. Cataldo A, Rebeck GW, Ghetri B, et al. Endocytic dis turbances distinguish among subtypes of Alzheimer'sdis ease and related disorders. Ann Neurol. 2001;50:661–665.
[53]. Takayama F, Hayashi Y, Wu Z, et al. Diurnal dynamic behaviour of microglia in response to infected bacteria through the UDP-P2Y6 receptor system. Sci Rep. 2016;6:30006.
[54]. Dorn BR, Dunn WA, Progulske-Fox A. Porphyromonasgingivalis traffics to autophagosomes in human coronary artery endothelial cells. Infect Immun. 2001;69:5698 5708.
[55]. Furuta N, Tsuda K, Omori H, et al. Porphyromonasgingivalis outer membrane vesicles enter human epithelial cells via an endocytic pathway and are sorted to lysosomal compartments. Infect Immun. 2009;77:4187–4196.
[56]. Wu Z, Ni J, Liu Y, et al. Cathepsin B plays a critical role in inducing Alzheimer's disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from Porphyromonasgingivalis in mice. Brain Behav Immun. 2017;65:350–361.
[57]. Olsen I, Yilmaz Ö. Modulation of inflammasome activity by Porphyromonasgingivalis in periodontitis and associated systemic diseases. J Oral Microbiol. 2016;8:30385.
[58]. Rapsinski GJ, Wynosky-Dolfi MA, Oppong GO, et al. Toll-like receptor 2 and NLRP3 cooperate to recognize a functional bacterial amyloid, curli. Infect Immun. 2015;83(2):693–701.
[59]. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–678.
[60]. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9 (8):857–865.
[61]. Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordi nates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into parti culate ligands in sterile inflammation. Nat Immunol. 2013;14(8):812–820.
[62]. Gold M, Khoury JE. β-amyloid, microglia, and the inflammasome in Alzheimer's disease. Semin Immunopathol. 2015;37:607–611.
[63]. Ding Y, Ren J, Yu H, et al. Porphyromonasgingivalis,a periodontitis causing bacterium, induces memory impairment and age-dependent neuroinflammation in mice. Immun Ageing. 2018;15:6.
[64]. Velsko IM, Chukkapalli SS, Rivera MF, et al. Active invasion of oral and aortic tissues by Porphyromonasgingivalis in mice causally links periodontitis and atherosclerosis. PLoS One. 2014;9:e97811.
[65]. Poole S, Singhrao SK, Chukkapalli S, et al. Active invasion of Porphyromonasgingivalis and infection induced complement activation in ApoE−/- mice brains. J Alzheimers Dis. 2015;43:67–80
[66]. Rokad F, Moseley R, Hardy RS, et al. Cerebral oxidative stress and microvasculature defects in TNF-α expres sing transgenic and Porphyromonasgingivalis-infected ApoE−/- mice. J Alzheimers Dis. 2017;60:359–369.
[67]. Singhrao SK, Chukkapalli S, Poole S, et al. Chronic Porphyromonasgingivalis infection accelerates the occurrence of age-related granules in ApoE−/- mice. J Oral Microbiol. 2017;9:1270602.
[68]. AkiyamaH,BargerS,BarnumS,etal.Inflammati onand Alzheimer's disease. Neurobiol Aging. 2000;21:383–421.
[69]. Tran L, Greenwood-Van Meerveld B. Age-associated remodeling of the intestinal epithelial barrier. J Gerontol A Biol Sci Med Sci. 2013;68:1045–1056.
[70]. Marques F, Sousa JC, Sousa N, et al. Blood-brain barriers in aging and in Alzheimer's disease. Mol Neurodegener. 2013;8:38.

[71]. Montagne A, Barnes SR, Sweeney MD, et al. Blood brain barrier breakdown in the aging human hippo campus. Neuron. 2015;85:296–302.
[72]. Halliday MR, Rege SV, Ma Q, et al. Accelerated peri cyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab. 2016;36:216–227.
[73]. Ilievski V, Zuchowska PK, Green SJ, et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta pro duction inwildtypemice. PLoSOne. 2018;13(10): e0204941.
[74]. Olsen I, Singhrao SK, Potempa J. Citrullination as a plausible link to periodontitis, rheumatoid arthritis, atherosclerosis and Alzheimer's disease. J Oral Microbiol. 2018;10(1):1487742.
[75]. Zhang J, Yu C, Zhang X, et al. Porphyromonasgingi valis lipopolysaccharide induces cognitive dysfunction, mediated by neuronal inflammation via activation of the TLR4 signalling pathway in C57BL/ 6 mice. J Neuroinflammation. 2018;15(1):37.
[76]. Olsen I, Singhrao SK. Importance of heterogeneity in Porhyromonasgingivalis lipopolysaccharide lipid A in tissue specific inflammatory signalling. J Oral Microbiol. 2018;10:1440128.
[77]. Liu Y, Wu Z, Nakanishi Y, et al. Infection of microglia with Porphyromonasgingivalis promotes cell migration and an inflammatory response through the gingipain-mediated activation of pro tease-activated receptor-2 in mice. Sci Rep. 2017;7 (1):11759.
[78]. Bäckman L, Small BJ, Fratiglioni L. Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain. 2001;124(1):96–102.
[79]. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572–580.
[80]. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181–193.
[81]. Rolim TDS, Fabri GM, Nitrini R, et al. Evaluation of patients with Alzheimer's disease before and after dental treatment. ArqNeuropsiquiatr. 2014;72(12):919–924